Neuropathic Pain Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

What combination of drivers is leading to accelerated growth in the neuropathic pain market?
The expansion of the neuropathic pain market is expected to be propelled by the increasing occurrence of chronic pain. Chronic pain, which is ongoing and extends beyond the usual recovery period of an illness or injury, typically persists for at least three to six months. The surge in chronic pain, including neuropathic conditions, necessitates effective therapeutic approaches, which in turn stimulates research, innovation, and spending in the development of better treatment options for improving symptom management and the quality of life. For illustration, the Scottish Health Survey conducted in 2022 by the Scotland-based Scottish Government revealed that in 2022, over one-third (38%) of Scottish adults experienced pain or discomfort for three months or more. The prevalence of such conditions was higher among women (43%) than men (33%). So, the escalating prevalence of chronic pain is a factor generating the growth of the neuropathic pain market. The neuropathic pain market is likely to expand further due to the anticipated increase in diabetes cases. Diabetes, a chronic medical condition involving elevated blood glucose levels, often results in neuropathies, which are the most common long-term complications of diabetes, affecting over 50% of diabetics during their lifetime. Diabetic peripheral neuropathy (DPN) is the most common type of such neuropathies and has the best-established treatment methods. For example, data from the UK's National Health Service (NHS) in June 2024 indicated a significant increase in the number of individuals under 40 affected by diabetes, from 173,166 in 2022 to 216,440 in 2023. This sharp increase underlines a worrying trend among the younger population and a quick increase in diabetes prevalence. Therefore, the surge in diabetes cases is spurring the growth of the neuropathic pain market.

Get Your Neuropathic Pain Market Report Here:
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

What is the projected compound annual growth rate (CAGR) of the neuropathic pain market from 2025 to 2034, and what factors influence it?
The market for neuropathic pain has been experiencing substantial growth in the past few years. The market, from being $5.35 billion in 2024, is projected to increase to $5.79 billion in 2025, marking an 8.2% compound annual growth rate (CAGR). The growth noted in the historical period resulted from a rise in the demand for drugs specialized for neuropathic pain, an escalating chronic pain epidemic, heightened demand for prescription-based treatments, and government initiatives.

The market for neuropathic pain is anticipated to witness substantial expansion in the coming years. It is projected to escalate to a value of $7.76 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. The upswing throughout the forecast period is likely due to the increased understanding of neuropathic pain, an ever-growing elderly population, a robust healthcare landscape, and the ease of accessing treatments for neuropathic pain. Notable trends for the forecast period encompass superior diagnostic methods, advancements in pain control techniques, medical research improvements, approval of new medicines, and strategic approaches.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

How are the latest trends influencing the growth of the neuropathic pain market?
Leading firms in the neuropathic pain industry are utilizing artificial intelligence (AI) to provide innovative diagnosis, personalized treatment strategies, real-time assessment, pharmaceutical research, and data-informed perspectives to augment patient outcomes and optimize pain management methods. For instance, Nevro Corp., an American medical device company, in March 2023, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This cutting-edge technology employs AI to tailor pain relief to individual patients' needs. The system, encompassing the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is constructed to address non-surgical back pain and painful diabetic neuropathy by adjusting to patients' feedback and responses. It utilizes a unique algorithm derived from comprehensive patient data and allows patients to alter their pain relief regimen using a smartphone app. The digital architecture of the system enables data gathering and possible updates. The technology aspires to improve pain relief through regularity and personalization, symbolizing a significant development in SCS therapy.

What are the major segments of the neuropathic pain market and their role in driving growth?
The neuropathic pain market covered in this report is segmented -

1) By Treatment: Medications, Multimodal Therapy
2) By Diagnosis: Imaging, Blood Tests And Physical Examination
3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications
4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12922

Which regions are key players in the growth of the neuropathic pain market?
North America was the largest region in the neuropathic pain market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the neuropathic pain market?
Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

What Is Covered In The Neuropathic Pain Global Market Report?

•Market Size Forecast: Examine the neuropathic pain market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neuropathic pain market for a structured understanding.
•Key Players Overview: Analyze major players in the neuropathic pain market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neuropathic pain market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neuropathic pain market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neuropathic pain market.
•Industry Challenges: Identify potential risks and obstacles affecting the neuropathic pain market.
•Competitive Landscape: Review strategic developments in the neuropathic pain market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.